Mirati Therapeutics @Mirati Twitter profile

Pinned Tweet

Mirati Therapeutics

4 months

Exciting news! Today, we officially completed our transaction with Bristol Myers Squibb. We look forward to continuing to deliver breakthrough therapies that target the genetic drivers of cancer as part of BMS. Follow our progress @BMSNews

0

5

Last Seen Profiles

@TYI_ER

@EncoreRodri

@tallulah_P0488

@cr4LwOLydN56819

@ModaPerea

@CristoBustos

@SLipglosses

@VmaniakJ

@vargoe21

@UnitedChartsuv

@industrystudies

@DejNope

@BramastaVerrell

@Chubaransano

@TymereBurton13

@AnCuRuadh

@davethebluesman

@silenthill_gf

@danimiklos_

@clearlake

@SeznamZpravy

@ARTONEPIECE1

@fraubauerfeind

@EhnGunnar

@emsations

@itshxllywood

@nxvy2

@DroudyArts

@JanWisniewski

@TrfanboyN

@jandakembangstw

@SterlGotti

@Famouss_Dev

@Taamgonet

@ShinkaiMaru5

@Hitten2

Mirati Therapeutics

@Mirati

1 year

Hear @KRASKickers Founder Terri Conneran’s perspective to understand why the approval of our new treatment option for #KRASG12C -mutated advanced non-small cell lung cancer is such an exciting moment for the cancer patient community. #NSCLC

Learn more about Mirati’s commitment

mirati.com

0

7

26

Mirati Therapeutics

@Mirati

2 years

Urgency, open-mindedness, accountability, and collaboration. Learn more about how these shared Mirati values ground us in our work for people living with #cancer :

3

21

Mirati Therapeutics

@Mirati

2 years

We’re excited to be on-site at #AACR22 and have the opportunity to convene with the #cancerresearch community on the latest breakthroughs in science. Visit us at booth #2153 .

0

18

Mirati Therapeutics

@Mirati

3 years

Was great to join @kRasKickers at their inaugural KRAS Kicker’s Connect event! The Mirati team is relentlessly kicking cancer’s #KRAS through our innovative science.

KRASKickers

@KRASKickers

3 years

WOW - So powerful from @Mirati for the @KRASKickers THANK You!! #HopeShared #KickKRAS #KickCancersKRAS #KRAS #LCSM #CRCSM

0

2

6

1

2

16

Mirati Therapeutics

@Mirati

3 years

We are proud to sponsor @kRasKickers Connect to discuss the #KRAS mutation and its role in cancer.

KRASKickers

@KRASKickers

3 years

Great time to mention Dr. Pasi Janne of @DanaFarber will be our featured #KRAS speaker in our #patients group. Thank you for your support @Mirati #KickCancersKRAS Join us LIVE Saturday!

0

5

12

1

4

15

Mirati Therapeutics

@Mirati

2 years

During #AACR22 , we look forward to sharing our latest #cancerresearch advancements and being back in person! Come visit us at booth #2153 .

1

0

11

Mirati Therapeutics

@Mirati

2 years

We’re proud to announce the U.S. FDA accepted the NDA for our KRASG12C inhibitor for patients with KRASG12C mutated 2L and advanced #lung #cancer . Read more:

0

1

13

Mirati Therapeutics

@Mirati

1 year

Announcing late-breaking investigational data in first line advanced/metastatic non-small cell lung cancer ( #NSCLC ) at #ESMOImmuno22 . Learn more:

2

13

Mirati Therapeutics

@Mirati

10 months

We are pleased to share that @CD_AACR has published preclinical data for MRTX1719 to treat #MTAP -Deleted cancers through a novel approach to MTA-cooperative #PRMT5 inhibition.

Learn more about the data

mirati.com

0

13

Mirati Therapeutics

@Mirati

1 year

The FDA has cleared the Investigational New Drug (IND) application for first-in-class oral #KRASG12D selective inhibitor for clinical evaluation, representing our third #KRAS signaling program to enter clinical development. Learn more

0

1

13

Mirati Therapeutics

@Mirati

2 years

Mirati is committed to bringing new treatments for patients with cancer. Our expanded-access program allows for potential access to investigational medical products in certain circumstances. Learn more:

0

2

13

Mirati Therapeutics

@Mirati

1 year

#KRAS mutations are the most common mutations in cancer, and until recently, they were difficult to target. Our team is dedicated to developing treatment options to target #KRASG12C .

0

2

12

Mirati Therapeutics

@Mirati

2 years

We’re proud to present new clinical research on our #KRASG12C inhibitor at the upcoming #ASCO22 meeting. Read more about what we’ll be sharing here:

0

4

12

Mirati Therapeutics

@Mirati

2 years

Announcing late-breaking data in patients with advanced #colorectalcancer harboring the #KRASG12C mutation at #ESMO22 . Learn more: #CRC

1

2

11

Mirati Therapeutics

@Mirati

2 years

We are pleased to share the publication of CNS penetration data for our #KRASG12C inhibitor in preclinical models and preliminary clinical data in patients with KRASG12C-mutated #lungcancer in Clinical Cancer Research. #AACR22 @CCR_AACR

0

3

12

Mirati Therapeutics

@Mirati

3 years

Excited to share initial clinical data in KRASG12C-mutated pancreatic cancer at 2021 AACR-NCI-EORTC Virtual International Conference, and a summary of the discovery & characterization of our KRAS G12D inhibitor. Tune to Plenary Session 5 today at 12:05 ET.

0

2

12

Mirati Therapeutics

@Mirati

2 years

Proud to announce that we submitted our marketing authorization application to the EMA for our #KRASG12C inhibitor for patients with non-small cell #lungcancer harboring the KRAS G12C mutation. Read more: #NSCLC

0

3

12

Mirati Therapeutics

@Mirati

1 year

Learn how our recently FDA approved treatment option for #KRASG12C -mutated advanced non-small cell lung cancer is creating the opportunity for us to continue advancing programs that make an impact for people with #cancer and their loved ones. #NSCLC

Read about our approval news

multivu.com

0

2

12

Mirati Therapeutics

@Mirati

1 year

FDA approved our new treatment option for the #lungcancer patient community. Learn more:

0

2

10

Mirati Therapeutics

@Mirati

3 years

Announcing clinical collaboration with @sanofi to evaluate combination of our #KRAS G12C inhibitor with their SHP2 inhibitor in KRAS G12C-mutated lung cancer. Read more

0

3

11

Mirati Therapeutics

@Mirati

2 years

Tune in tomorrow to hear our CSO James Christensen discuss his experience leading scientific programs from the early stages to the clinic, including Mirati’s #KRASG12C inhibitor, during an @endpts webinar. Register today:

0

11

Mirati Therapeutics

@Mirati

2 years

How does our Drug Discovery team’s spirit of invention and scientific creativity aid the discovery of new treatment options for patients with hard-to-treat cancers?

Learn about our Drug Discovery team from Matt Marx

mirati.com

0

1

11

Mirati Therapeutics

@Mirati

2 years

Tune-in tomorrow 1/21 to hear our #KRASG12C data presentation at ASCO GI starting at 7am PT / 10am ET and find us at booth #19 #GI22

1

11

Mirati Therapeutics

@Mirati

3 years

Dr. Mark Socinski of the @AdventHealth Cancer Institute offers a thoughtful perspective on KRASG12C mutations and explains why sustained inhibition may be required to effectively disrupt tumor activity.

2

0

11

Mirati Therapeutics

@Mirati

2 years

Nishma Held is one of our many colleagues whose personal experiences with #cancer motivated them to pursue careers helping patients. On #WorldLungCancerDay , learn about our deep commitment to patients.

Explore our commitment to the patient community

mirati.com

0

1

11

Mirati Therapeutics

@Mirati

8 months

We’re pleased to share that adagrasib + #EGFR inhibitor (cetuximab or panitumumab) has been added to the @NCCN 's Guidelines for Colon and Rectal cancers. #coloncancer #rectalcancer View the updated guidelines:

0

3

10

Mirati Therapeutics

@Mirati

2 years

Medical oncologist, @MLJohnsonMD2 discusses #KRAS research and the importance of biomarker testing. Learn more:

1

2

10

Mirati Therapeutics

@Mirati

2 years

We are boldly pursuing science that aims to move the needle on standards of care, making the “undruggable,” druggable. Read about our 2021 financial results and recent corporate updates:

0

1

10

Mirati Therapeutics

@Mirati

2 years

Pleased to announce positive results from the registration-enabling Phase 2 cohort evaluating our #KRAS G12C inhibitor in patients with non-small cell #lungcancer harboring the #KRASG12C mutation. Learn more: #NSCLC #ASCO22

0

1

9

Mirati Therapeutics

@Mirati

2 years

Congratulations to this year’s Atlanta Diamond Foundation scholarship recipients. We’re proud to contribute to this program, which empowers local students attending colleges and universities with a focus on #STEM .

Learn about the community organizations we support

mirati.com

0

1

10

Mirati Therapeutics

@Mirati

2 years

We celebrate our female employees and their commitment to being positive change agents for patients and in their communities. We're honored to share their views. #InternationalWomensDay

0

9

Mirati Therapeutics

@Mirati

2 years

Listen to @JackWestMD of @CityofHope share the challenges of #KRASG12C inhibition.

Learn about the latest KRAS G12C research

krasregeneration.com

0

1

9

Mirati Therapeutics

@Mirati

2 years

We’re working toward finding meaningful breakthroughs for people with #cancer and fostering an inclusive #culture that encourages innovation and collaboration.

Learn about our mission and commitment to patients

mirati.com

0

8

Mirati Therapeutics

@Mirati

2 years

Today, we show appreciation for our employees’ relentless drive to restore hope for #cancer patients with a well-earned day of rest, which we call a Mirati Day. Learn about what makes our team special: #EmployeeAppreciationDay

0

8

Mirati Therapeutics

@Mirati

1 year

New article from @NatRevDrugDisc discusses our latest developments targeting #KRAS , including our investigation into #KRASG12D .

Nature Reviews Drug Discovery

@NatRevDrugDisc

1 year

News feature: The KRAS crowd targets its next cancer mutations Clinic-ready inhibitors, degraders and molecular glues are pushing cancer frontiers by targeting KRAS variants including KRAS-G12D.

0

9

30

0

2

9

Mirati Therapeutics

@Mirati

2 years

Learn more from Dr. John Heymach, MD, about the strides to develop new treatment options for KRAS-mutant cancers.

0

2

9

Mirati Therapeutics

@Mirati

2 years

We’re honored to be able to support @BiocomInstitute and its mission to develop a strong and diverse #lifesciences workforce in California.

Biocom California Institute

@BiocomInstitute

2 years

Huge thanks to our friends and partners at @Mirati for their incredibly generous support of @BiocomInstitute this year. Mirati's support positively impacts #veterans and #firstgeneration college graduates entering the life science industry and our Life Science XP program.

0

1

3

0

9

Mirati Therapeutics

@Mirati

2 years

As a @sdut Top Work Place award winner, the Mirati team is unified by our dedication to restoring hope for patients with #cancer . Come be part of something bigger: #SanDiego

0

9

Mirati Therapeutics

@Mirati

2 years

We shared exciting new data at ASCO GI for our investigational #KRAS G12C inhibitor in patients with pancreatic cancer, and other GI tumors harboring a #KRASG12C mutation. Learn more. #GI22

1

2

9

Mirati Therapeutics

@Mirati

2 years

We’re excited to be at #ASCO22 to present our latest advancements in #cancerresearch . Visit us at booth #2097 .

Learn more about our science

mirati.com

0

8

Mirati Therapeutics

@Mirati

2 years

Our relentless pursuit of breakthrough #research aims to address unmet medical needs for people living with #cancer . Learn about our targeted oncology programs here:

Explore our latest scientific advancements

mirati.com

0

1

7

Mirati Therapeutics

@Mirati

3 years

Proud to announce a new clinical collaboration with $VTSM to evaluate the combination of their RAF/MEK inhibitor and our #KRAS G12C inhibitor in #KRAS G12C-mutant #NSCLC . #Oncology #CancerResearch #ClinicalTrials #LCSM . Read more

1

8

Mirati Therapeutics

@Mirati

2 years

Read about our take on trending topics in science that impact our work and patients with #cancer :

0

8

Mirati Therapeutics

@Mirati

2 years

As the year comes to a close, we wanted to send a huge thank you to all Mirati employees and partners. We are proud of our achievements and look forward to maintaining this momentum into 2022! #MiratiProud

1

0

8

Mirati Therapeutics

@Mirati

2 years

Join us for our poster presentation at #ESMO22 , where we’re excited to present our late-breaking data in patients with advanced #colorectalcancer harboring the #KRASG12C mutation.

1

7

Mirati Therapeutics

@Mirati

1 year

At the 41st Annual J.P. Morgan Healthcare Conference, we’re excited to share the latest on how we’re continuing to innovate and deliver for cancer patients with high unmet need. #JPM2023

Learn more about Mirati

mirati.com

0

1

7

Mirati Therapeutics

@Mirati

2 years

We believe our employees' skills and generosity can positively impact the communities in which we work and live. Learn more about Mirati Gives: #Volunteer #CommunityService

0

8

Mirati Therapeutics

@Mirati

9 months

Join us at WCLC for 2-year follow-up results of the KRYSTAL-1 trial evaluating patients with advanced or metastatic #KRASG12C -mutated #NSCLC #WCLC23 .

0

7

Mirati Therapeutics

@Mirati

2 years

We’re relentlessly focused on addressing the unmet medical need in #KRASG12C -mutated #NSCLC . Hear about the latest in KRAS from Medical Oncologist Jack West, MD. #ASCO22

Explore our science

mirati.com

0

7

Mirati Therapeutics

@Mirati

2 years

We’re focused on advancing our understanding of KRAS mutations to address unmet needs for people living with #cancer .

Explore our work in KRAS

mirati.com

0

1

8

Mirati Therapeutics

@Mirati

3 years

Mirati CSO James Christensen shares his thoughts on the role of #KRAS mutations in colon cancer and opportunities for targeting the KRAS signaling network for therapeutic intervention during the UC San Diego Moores Cancer Symposium. Read more:

1

0

8

Mirati Therapeutics

@Mirati

1 year

During #BlackHistoryMonth , @PanCAN is bringing together a panel of community members and experts who are working to treat #pancreaticcancer patients in the Black community and beyond. Tune into this empowering conversation on 2/23 and RSVP at .

A Conversation About Pancreatic Cancer in the Black Community - Thursday, 2/23

Join PanCAN on February 23, at 11 a.m. PT / 2 p.m. ET, for a Black History Month panel discussion about the power of patient advocacy to create change.

pancan.org

PanCAN

@PanCAN

1 year

On Feb. 23, we'll dig into healthcare disparities & what needs to be done to promote health equity in #pancreaticcancer screening, treatment, and research during our webinar, “A Conversation About Pancreatic Cancer in the Black Community”. 💬 RSVP at ➡️ .

0

2

6

0

3

8

Mirati Therapeutics

@Mirati

2 years

Join us for a poster presentation at #ESMO22 , where we’ll be presenting updated safety data for patients with #KRASG12C -mutated non-small cell #lungcancer . #NSCLC

0

3

8

Mirati Therapeutics

@Mirati

2 years

Wishing a warm welcome to our new group of Mirati interns! To kick off this summer’s #internship program, interns representing different functions across the company got to know each other better through a fun game of virtual Mingle Bingo.

0

8

Mirati Therapeutics

@Mirati

2 years

To turn possibility into reality for patients, we are relentless in our pursuit of scientific advancement.

Explore our science

mirati.com

0

8

Mirati Therapeutics

@Mirati

1 year

. @Qiagen has announced the approval of its therascreen KRAS as a companion diagnosis test to KRAZATI® (adagrasib), for patients living with non-small cell lung cancer ( #NSCLC ) that have a #KRASG12C mutation. Learn more:

0

1

8

Mirati Therapeutics

@Mirati

2 years

Learn more from medical oncologist @MLJohnsonMD2 about central nervous system (CNS) metastases in KRAS-mutated #lungcancer . #ASCO22

Watch to learn about the impact on patients

krasregeneration.com

1

6

Mirati Therapeutics

@Mirati

2 years

Medical oncologist John Heymach, MD discusses his perspective on why #KRAS biomarkers are unique and the implications for addressing KRAS-mutated cancers. Read more:

0

7

Mirati Therapeutics

@Mirati

2 years

As #ASCO22 comes to an end, we’re proud of the clinical advances in KRASG12C-mutated #lungcancer that we presented. Keep following along for the latest research as we advance our mission to transform the lives of patients with #cancer and their loved ones.

0

7

Mirati Therapeutics

@Mirati

2 years

Our mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with #cancer . Read how we’re serving our communities and addressing sustainability issues in our inaugural corporate sustainability report.

0

6

Mirati Therapeutics

@Mirati

2 years

We’re excited to welcome Norint Tung, our new PharmD fellow participating in the UC San Diego Skaggs School of Pharmacy and Mirati fellowship program to prepare for a successful career in #biotech and #pharma . @UCSDSkaggsSOP

Learn more about the fellowship program

ucsd.edu

1

7

Mirati Therapeutics

@Mirati

2 years

“Mirati continues to advance the development of a broad portfolio of targeted oncology medicines.” – David Meek, Mirati CEO Read about our second quarter 2022 earnings and recent corporate updates.

Read the full update

mirati.com

0

1

7

Mirati Therapeutics

@Mirati

3 years

The #FDA has granted breakthrough therapy designation for our investigational #KRAS asset for the treatment of patients with non-small cell lung cancer who harbor the KRAS G12C mutation. Read more here:

0

2

7

Mirati Therapeutics

@Mirati

2 years

Learn more from our CEO David Meek about why Mirati is well-positioned to deliver innovative targeted #cancer therapies and have a meaningful impact for patients:

Read about the bright future of targeted oncology

mirati.com

1

0

6

Mirati Therapeutics

@Mirati

2 years

We’re pleased to announce that Laurie Stelzer has been appointed as Mirati’s Chief Financial Officer. Laurie brings 25 years of #biopharma industry experience to her new role. Learn more:

0

7

Mirati Therapeutics

@Mirati

3 years

Oncologist @AlexSpiraMDPhD reflects on advancements in KRAS research. As targeted therapies become available for patients, identifying the right treatment course with selective and sustained targeted inhibition for cancers with a KRAS G12C mutation becomes increasingly important.

0

2

7

Mirati Therapeutics

@Mirati

3 years

We’re presenting Phase 2 combination results at #ESMO21 on our investigational receptor tyrosine kinase inhibitor in patients who experienced clinical benefit on a prior checkpoint inhibitor and subsequent disease progression. Tune in tomorrow at 5:20am PT/8:20am ET on Channel 4.

0

1

7

Mirati Therapeutics

@Mirati

2 years

During #ELCC22 , we’re pleased to sponsor a symposium discussion on emerging research advances in non-small cell #lungcancer . #NSCLC

0

7

Mirati Therapeutics

@Mirati

1 year

Mirati honors patients living with cancer during National Cancer Survivor Month. Visit our new patient stories page to read about Terri Conneran’s journey. #CelebrateSurvivorship

Terri Conneran shares her cancer journey.

mirati.com

0

2

7

Mirati Therapeutics

@Mirati

1 year

For oncologists like @AlexSpiraMDPhD , our recent FDA approval means the ability to provide more options for adults with #KRASG12C -mutated advanced non-small cell lung cancer. #NSCLC

Learn about how we’re advancing treatment options

mirati.com

0

6

Mirati Therapeutics

@Mirati

1 year

This year, we partnered with the @SDFoodBank for a holiday food drive. We’re proud of our employees, whose combined donations will provide 4,700 meals for the community. #MiratiGives

1

5

Mirati Therapeutics

@Mirati

1 year

Our colleague, Roderic Toney, shares his perspective on the importance of sustaining a culture of inclusion to strengthen, inspire and cultivate a culture of belonging at Mirati. #BlackHistoryMonth #DEI

0

7

Mirati Therapeutics

@Mirati

1 year

From our scientific innovation to our people, hear from Mirati’s Chief Commercial Officer, Ben Hickey, about how Mirati is poised for continued commercial success in the oncology space following our recent approval.

Mirati’s approach to building a commercialization organization

mirati.com

0

7

Mirati Therapeutics

@Mirati

2 years

Announcing late-breaking data in patients with KRASG12C-mutated non-small cell #lungcancer with active and untreated central nervous system metastases. Learn more: #NSCLC #ASCO22

0

1

6

Mirati Therapeutics

@Mirati

2 years

As Mirati celebrates #HispanicHeritageMonth , we celebrate team members like Danielle Hernandez. We are more successful, creative, and resilient in our pursuit of helping patients with cancer because of our diverse & inclusive community.

0

2

7

Mirati Therapeutics

@Mirati

2 years

Learn more about how our commitment to our core values, our dedication to creating a sense of belonging and inclusion, and our passion for helping patients unify Team Mirati.

Explore our company culture

mirati.com

0

7

Mirati Therapeutics

@Mirati

3 years

Proud of the Mirati team and the many ways they give back to the San Diego community. #InternationalDayofCharity

0

7

Mirati Therapeutics

@Mirati

3 years

When you work with us, you’ll not only grow your career, but you’ll also be making an impact on patients’ lives. And that’s something to feel good about. Explore our recent #JobOpportunities :

1

0

6

Mirati Therapeutics

@Mirati

2 years

We’re excited to be at #ESMO22 , where we look forward to convening around the latest #oncology advancements. Visit us at booth 448.

0

1

7

Mirati Therapeutics

@Mirati

1 year

This #AAPIHeritageMonth , Linh Alejandro, our Director of Medical Affairs Strategy, shares how her experience growing up as the daughter of Vietnamese refugees shaped her perception of the #Healthcare industry.

0

1

6

Mirati Therapeutics

@Mirati

3 years

Tune-in tomorrow, November 3, at 10:30 a.m. EST | 7:30 a.m. PST as Linh Alejandro speaks about KRAS G12C in colorectal cancer (CRC) at the #GICancerSummit

0

1

6

Mirati Therapeutics

@Mirati

1 year

From her role at Mirati to her personal experience with her son’s diagnosis, Rochelle Williams-Belizaire shares why she has an unwavering passion for health equity and clinical collaboration. #BlackHistoryMonth #HealthEquity

0

6

Mirati Therapeutics

@Mirati

2 years

Learn more from medical oncologist @MLJohnsonMD2 of @SarahCannonDocs on the future of #KRAS therapies.

0

6

Mirati Therapeutics

@Mirati

2 years

Susan Welsh, leader of Mirati’s Pharmacovigilance & Safety group, will join the global #pharmacovigilance community at the World Drug Safety Congress Americas, where she will chair the opening and closing sessions. #DrugSafetyUS @WDS_event

Learn more about Susan’s presence at the congress

terrapinn.com

0

1

6

Mirati Therapeutics

@Mirati

1 year

We’re pleased to share that adagrasib has been added to the @NCCN ’s Guidelines for pancreatic ductal adenocarcinoma (PDAC). View the updated guidelines:

0

2

6

Mirati Therapeutics

@Mirati

2 years

Collaboration is essential for advancing our expanding pipeline to meet the needs of #patients . #JPM2022

0

6

Mirati Therapeutics

@Mirati

3 years

Mirati CSO James Christensen takes part in the 17th UC San Diego Health Moores Cancer Center Symposium. Tune in tomorrow at 2:15pm PST to hear his talk on our latest #KRAS research.

0

6

Mirati Therapeutics

@Mirati

2 years

Join us today in Hall D1 or virtually, where Joshua K. Sabari, MD will present late-breaking data in KRASG12C-mutated non-small cell #lungcancer with active and untreated central nervous system metastases. #ASCO22

0

1

4

Mirati Therapeutics

@Mirati

2 years

Learn about Mirati Chief Legal Officer, Reena Desai, including her career journey and commitment to #DEI , in a recent @AHL_Magazine article:

0

1

5

Mirati Therapeutics

@Mirati

3 years

Today is a Mirati Day. A day of rest to show our deep appreciation for the hard work and relentless focus our employees have toward delivering on our mission.

0

6

Mirati Therapeutics

@Mirati

1 year

Learn about how our employees’ skills and generosity positively impacted our local communities in 2022. Thank you to Team Mirati and everyone who has helped to make this year a success.

0

6

Mirati Therapeutics

@Mirati

2 years

Supporting the communities where we live and work is as important as the work we do. Learn more about how we support our local communities through Mirati Gives. #volunteer #giveback

See how we give back

mirati.com

1

0

6

Mirati Therapeutics

@Mirati

3 years

How do we progress #KRAS therapies to offer sustained targeted inhibition, an attribution that could be important to treat KRASG12C mutated cancers as the KRASG12C protein regenerates every 24-48 hours? Pasi A. Jänne, MD, PhD shares his perspective.

0

1

7

Mirati Therapeutics

@Mirati

2 years

Great people, exciting scientific platforms and the potential to deliver innovation to patients with #cancer . Come join our team at Mirati. #JPM2022

0

1

5

Mirati Therapeutics

@Mirati

2 years

The #KRAS mutation occurs in approximately 14% of patients with non-small-cell lung cancer. Learn more about Mirati's KRAS clinical development program here:

0

6

Mirati Therapeutics

@Mirati

3 years

We are working to better understand the impact of co-occurring mutations STK11 and #KRAS G12C on patient outcomes. Tune in at #ASCO21 for our @GuardantHealth and @MassGeneralNews collaboration data results.

Guardant Health

@GuardantHealth

3 years

At #ASCO21 , we present new data from a study in collaboration with Massachusetts General Hospital and @Mirati showing how our GuardantINFORM real-world evidence platform was used to identify unmet needs for patients with lung adenocarcinomas. #RWE #KRAS

0

3

7

0

3

6

Mirati Therapeutics

@Mirati

2 years

During #WCLC22 , we’re pleased to sponsor a symposium on the future of non-small cell #lungcancer . Learn more: #NSCLC

1

6

Mirati Therapeutics

@Mirati

3 years

Kenna Anderes, Ph.D., vice president, translational medicines and companion diagnostics, shares her views on exploiting #cancer ’s weaknesses with personalized medicine. Read more:

0

6

Mirati Therapeutics

@Mirati

2 years

“2021 was an important year of growth, progress and strong execution for Mirati.” – David Meek, Mirati CEO Read our Annual Report here:

0

6

Mirati Therapeutics

@Mirati

1 year

We’re excited to announce a strategic partnership with @SarahCannonDocs focused on making community-based #Oncology #ClinicalTrials more representative of diverse patient populations. Learn more:

0

1

6